Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia

被引：20

作者：

Yan, Yinfa ^{[1
]}

Zhou, Ping ^{[1
]}

Rotella, David P. ^{[1
]}

Feenstra, Rolf ^{[2
]}

Kruse, Chris G. ^{[2
]}

Reinders, Jan-Hendrik ^{[2
]}

van der Neut, Martina ^{[2
]}

Lai, Margaret ^{[3
]}

Zhang, Jean ^{[3
]}

Kowal, Dianne M. ^{[3
]}

Carrick, Tikva ^{[3
]}

Marquis, Karen L. ^{[3
]}

Pausch, Mark H. ^{[3
]}

Robichaud, Albert J. ^{[1
]}

机构：

[1] Wyeth Res, Chem Sci, Princeton, NJ 08543 USA

[2] Solvay Pharmaceut Res Labs, NL-1381 CP Weesp, Netherlands

[3] Wyeth Res, Discovery Neurosci, Princeton, NJ 08543 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 09期

关键词：

Serotonin reuptake inhibitor; Dopamine D-2 partial agonist; Schizophrenia; DEPRESSION; ARIPIPRAZOLE; COMBINATION; OLANZAPINE; FLUOXETINE;

D O I：

10.1016/j.bmcl.2010.02.105

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A dihydroquinolinone moiety was found to be a potent serotonin reuptake inhibitor pharmacophore when combined with certain amines. This fragment was coupled with selected D-2 ligands to prepare a series of dual acting compounds with attractive in vitro profiles as dopamine D-2 partial agonists and serotonin reuptake inhibitors. Structure-activity studies revealed that the linker plays a key role in contributing to D-2 affinity, function, and SRI activity. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2983 / 2986

页数：4

共 50 条

[31] TREATMENT OF SCHIZOPHRENIA WITH OBSESSIVE-COMPULSIVE FEATURES WITH SEROTONIN REUPTAKE INHIBITORS
HWANG, MY
MARTIN, AM
LINDENMAYER, JP
STEIN, D
HOLLANDER, E
AMERICAN JOURNAL OF PSYCHIATRY, 1993, 150 (07): : 1127 - 1127
[32] Paraphilias in schizophrenia: Differential diagnosis and treatment with selective serotonin reuptake inhibitors
Yang, Fei-Wen
Liang, Chih-Sung
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2010, 34 (06): : 1126 - 1127
[33] Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors
Wadenberg, Marie-Louise G.
FUTURE NEUROLOGY, 2007, 2 (02) : 153 - 165
[34] Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors
Wood, Martyn
Dubois, Vanessa
Scheller, Dieter
Gillard, Michel
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (04) : 1124 - 1135
[35] Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, Nicholas
Hope, Judith
Schwartz, Darren
McLennan, Harold
Copolov, David
Meadows, Graham
CNS DRUGS, 2020, 34 (05) : 473 - 507
[36] Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Nicholas Keks
Judith Hope
Darren Schwartz
Harold McLennan
David Copolov
Graham Meadows
CNS Drugs, 2020, 34 : 473 - 507
[37] Bifeprunox - A partial dopamine-receptor agonist for the treatment of schizophrenia
Watanabe, Mark D.
FORMULARY, 2007, 42 (06) : 371 - +
[38] State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia
Sonnenschein, Susan F.
Gill, Kathryn M.
Grace, Anthony A.
NEUROPSYCHOPHARMACOLOGY, 2019, 44 (03) : 572 - 580
[39] State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia
Susan F. Sonnenschein
Kathryn M. Gill
Anthony A. Grace
Neuropsychopharmacology, 2019, 44 : 572 - 580
[40] STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA
Sonnenschein, Susan
Gill, Kathryn
Grace, Anthony
SCHIZOPHRENIA BULLETIN, 2018, 44 : S338 - S338

← 1 2 3 4 5 →